These results suggest that FOXF2 directly transactivates the expression of BMP4 and SMAD1, implying that FOXF2 programs osteomimetic phenotype in breast cancer cells by pleiotropic transactivation of BRGs and the BMP/SMAD signaling pathway. This evidence concerns the gene FOXF2 and breast carcinoma.